As previously disclosed, on March 22, 2016, the Nasdaq Stock Market (“Nasdaq”) notified CTI BioPharma Corp. (the “Company”) that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2). On January 18, 2017, Nasdaq notified the Company that the closing bid price for the Company’s common stock had remained at $1.00 or greater for ten consecutive business days and, accordingly, the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2) and this matter is now closed.

About CTI BIOPHARMA CORP. (NASDAQ:CTIC)

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

CTI BIOPHARMA CORP. (NASDAQ:CTIC) Recent Trading Information

CTI BIOPHARMA CORP. (NASDAQ:CTIC) closed its last trading session down -0.10 at 4.97 with 201,645 shares trading hands.